Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
=== Biofilm formation === The first step in the formation of biofilms is adhesion. The initial bacterial adhesion to surfaces involves the adhesin–receptor interactions. Certain polysaccharides, lipids and proteins in the matrix function as the adhesive agents. EPS also promotes cell–cell cohesion (including interspecies recognition) to facilitate microbial aggregation and biofilm formation. In general, the EPS-based matrix mediates biofilm assembly as follows. First, the EPS formation takes place at the site of adhesion, it will be either produced on bacterial surfaces or secreted on the surface of attachment, and form an initial polymeric matrix promoting microbial colonization and cell clustering. Next, continuous production of EPS further expands the matrix in 3 dimensions while forming a core of bacterial cells. The bacterial core provides a supporting framework, and facilitates the development of 3D clusters and aggregation of microcolonies. Studies on P. aeruginosa, B. subtilis, V. cholerae, and S. mutans suggested that the transition from initial cell clustering to microcolony appears to be conserved among different biofilm-forming model organisms. As an example, S. mutans produces an exoenzyme, called glucosyltransferase (Gtf), which synthesizes glucans in situ using host diet sugars as substrates. Gtfs even bind to the bacteria that do not synthesize Gtfs, and therefore, facilitate interspecies and interkingdom coadhesion.
{\displaystyle {\begin{aligned}N(t)&=N_{0}\left({\frac {1}{2}}\right)^{\frac {t}{t_{1/2}}}\\N(t)&=N_{0}2^{-{\frac {t}{t_{1/2}}}}\\N(t)&=N_{0}e^{-{\frac {t}{\tau }}}\\N(t)&=N_{0}e^{-\lambda t}\end{aligned}}}
==== Morphological plasticity in the supraoptic nucleus ==== Anatomical studies using electron microscopy have shown that the morphology of the supraoptic nucleus is remarkably adaptable. For example, during lactation there are large changes in the size and shape of the oxytocin neurons, in the numbers and types of synapses that these neurons receive, and in the structural relationships between neurons and glial cells in the nucleus. These changes arise during parturition, and are thought to be important adaptations that prepare the oxytocin neurons for a sustained high demand for oxytocin. Oxytocin is essential for milk let-down in response to suckling. These studies showed that the brain is much more "plastic" in its anatomy than previously recognized, and led to great interest in the interactions between glial cells and neurons in general.
Sources: en.wikipedia.org
== Firazyr (icatibant) == Jerini's lead compound Firazyr (icatibant), is an inhibitor of the action of the hormone bradykinin on its B2 receptor. This compound was in-licensed from Aventis in 2001. It has been approved for hereditary angioedema in all member states of the European Union in July 2008. The drug was granted FDA approval on August 25, 2011.
The history of visual art in Portugal dates back into the Paleolithic. An early evidence showing an attempt at depicting motion was found at the Prehistoric Rock Art Sites in the Côa Valley and Siega Verde. Over time, foreign and native influences, together with advancements in manufacturing, developed distinctive art styles, such as the Manueline and Pombaline, and also a number of crafts that are typical of Portugal, namely the azulejo, talha dourada, and Portuguese pavement. Historically, Christianity played an influential role in Portuguese art and was a recurrent theme in many art forms, including painting. Throughout the country's history, artwork in Portugal was typically done by local artists who, depending on location, followed different variations in style, giving Portugal a diverse array of artistic styles throughout the country, an example of this being the thatch houses of Santana, in Madeira.
==== Tulips ==== Tulips have been cultivated since at least the tenth century in Persia. Tulip production has two main markets: cut flowers and bulbs. The latter are used, in turn, to meet the demand for bulbs for parks, gardens, and home use and, secondly, to provide the necessary bulbs for cut flower production. International trade in cut flowers has an approximate total value of 11 billion euros, which provides an indication of the economic importance of this activity. The main producer of tulip bulbs is the Netherlands, a country that accounts for 87% of the global cultivated area, with approximately 12,000 hectares. Other leading producers include Japan, France and Poland. Approximately ten other countries produce commercial tulips, largely for the domestic market. By contrast, the Netherlands is the leading international producer, to the extent of 4 billion bulbs per annum. Of these, 53% are used for the cut flower market and the remainder for the dry bulb market. Of the cut flowers, 57% are used for the domestic market in the Netherlands and the remainder exported. Original Tulipa species can be obtained for ornamental purposes, such as T. tarda and T. turkestanica. These are referred to as species, or botanical, tulips, and tend to be smaller plants but better at naturalising than the cultivated forms. Breeding programs have produced a wide range of tulip types, enabling blooming through a much longer season by creating early, mid- and late spring varieties.
Equine polysaccharide storage myopathy (EPSM, PSSM, EPSSM) is a hereditary glycogen storage disease of horses that causes exertional rhabdomyolysis. It is currently known to affect the following breeds: American Quarter Horses, American Paint Horses, Warmbloods, Cobs, Dales Ponies, Thoroughbreds, Arabians, New Forest ponies, and a large number of heavy horse breeds. While incurable, PSSM can be managed with appropriate diet and exercise. There are currently 2 subtypes, known as Type 1 PSSM and Type 2 PSSM.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.